BIOMAT Database Logo BIOMAT Database Logo

Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. 2020

Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Section of Cardiovascular Medicine Department of Internal Medicine Yale University School of Medicine New Haven CT.

Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter-defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies (NICMs) and evaluated factors associated with mortality among patients with cardiac amyloidosis. Methods and Results Using National Cardiovascular Data Registry's ICD Registry data between April 1, 2010 and December 31, 2015, we created a 1:5 propensity-matched cohort of patients implanted with ICDs with cardiac amyloidosis and NICM. We compared mortality between those with cardiac amyloidosis and matched patients with NICM using Kaplan-Meier survival curves and Cox proportional hazards models. We also evaluated risk factors associated with 1-year mortality in patients with cardiac amyloidosis using multivariable Cox proportional hazards regression models. Among 472 patients with cardiac amyloidosis and 2360 patients with propensity-matched NICMs, 1-year mortality was significantly higher in patients with cardiac amyloidosis compared with patients with NICMs (26.9% versus 11.3%, P<0.001). After adjustment for covariates, cardiac amyloidosis was associated with a significantly higher risk of all-cause mortality (hazard ratio [HR], 1.80; 95% CI, 1.56-2.08). In a multivariable analysis of patients with cardiac amyloidosis, several factors were significantly associated with mortality: syncope (HR, 1.78; 95% CI, 1.22-2.59), ventricular tachycardia (HR, 1.65; 95% CI, 1.15-2.38), cerebrovascular disease (HR, 2.03; 95% CI, 1.28-3.23), diabetes mellitus (HR, 1.55; 95% CI, 1.05-2.27), creatinine = 1.6 to 2.5 g/dL (HR, 1.99; 95% CI, 1.32-3.02), and creatinine >2.5 (HR, 4.34; 95% CI, 2.72-6.93). Conclusions Mortality after ICD implantation is significantly higher in patients with cardiac amyloidosis than in patients with propensity-matched NICMs. Factors associated with death among patients with cardiac amyloidosis include prior syncope, ventricular tachycardia, cerebrovascular disease, diabetes mellitus, and impaired renal function.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Timing of prophylactic implantable cardioverter-defibrillator implantation in patients with cardiomyopathy.
July 2012, The American journal of cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Tachycardia-induced cardiomyopathy unmasked with implantable cardioverter defibrillator implantation.
October 2013, The Canadian journal of cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Survival after implantable cardioverter-defibrillator implantation in the elderly.
June 2013, Circulation,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Chagas cardiomyopathy and implantable cardioverter defibrillator implantation: similarities and differences with dilated cardiomyopathy.
February 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
September 2011, Journal of the American College of Cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Implantable cardioverter-defibrillator in hypertrophic cardiomyopathy.
August 2018, Global cardiology science & practice,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Patient Activity and Survival Following Implantable Cardioverter-Defibrillator Implantation: The ALTITUDE Activity Study.
May 2015, Journal of the American Heart Association,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Response: Impact of implantable cardioverter defibrillator on survival in patients with nonischemic dilated cardiomyopathy.
October 2023, Clinical cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Impact of implantable cardioverter defibrillator on survival in patients with non-ischemic dilated cardiomyopathy.
October 2023, Clinical cardiology,
Angela Y Higgins, and Amarnath R Annapureddy, and Yongfei Wang, and Karl E Minges, and Rachel Lampert, and Lynda E Rosenfeld, and Daniel L Jacoby, and Jeptha P Curtis, and Edward J Miller, and James V Freeman
Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender.
February 2014, Heart (British Cardiac Society),
Copied contents to your clipboard!